TTD | Drug: D03GAY

Drug General Information
Drug ID	D03GAY
Former ID	DIB013185
Drug Name	H-409/22
Drug Type	Small molecular drug
Indication	Cardiovascular disorder [ICD10:I00-I99]		Discontinued in Phase 2	[547165]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Formula	C28H33N5O3
Canonical SMILES	CC(C1=CC=C(C=C1)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C2=CC=CC=C<br />2)C3=CC=CC=C3
InChI	1S/C28H33N5O3/c1-19(20-14-16-23(34)17-15-20)32-26(35)24(13-8-18-31-28(29)30)33-27(36)25(21-9-4-2-5-10-21)22-11-6-3-7-12-22/h2-7,9-12,14-17,19,24-25,34H,8,13,18H2,1H3,(H,32,35)(H,33,36)(H4,29,30,31)/t19-,24-/m1/s1
InChIKey	AOUQZUZEYSDMEZ-NTKDMRAZSA-N
PubChem Compound ID	5311439
PubChem Substance ID	7980621, 14932780, 15504507, 39341114, 51292288, 114156100, 227787860, 242832189
Target and Pathway
Target(s)	Neuropeptide Y receptor type 1	Target Info	Antagonist	[525884]
KEGG Pathway	cAMP signaling pathway
KEGG Pathway	Neuroactive ligand-receptor interaction
NetPath Pathway	FSH Signaling Pathway
Reactome	Peptide ligand-binding receptors
Reactome	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	Endothelin Pathways
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 547165	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013561)
Ref 525884	In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information